Program for early detection and management of side effects in metastatic cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the ApricityCare program aimed at identifying early clinical signs of treatment-related adverse events in patients with metastatic cancer. The primary objective is to determine the rate of therapy discontinuation due to toxicity among participants using the program. Secondary objectives include measuring participant engagement with the program, frequency of symptom reporting, and response times to reported symptoms. The study focuses on patients receiving systemic anti-cancer therapy and utilizes a smartphone application for monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years of age or older
* Confirmed diagnosis of cancer

  * Part 1 (Run-in Phase): Only patients with prostate, kidney, and/or bladder cancer will be enrolled with either localized or metastatic disease.
  * Part 2 (Expansion Phase): Metastatic patients will be enrolled. Note, evaluable metastatic patients from Ppart 1 will be counted in Cohort A as described in section 8.4.
* Planned to receive systemic anti-cancer therapy
* Ability to understand and the willingness to sign a written informed consent document
* Ability to speak, read, and understand one of the following languages: English, Spanish, Mandarin and Cantonese Chinese
* Ownership of a smartphone and willingness to use it as outlined by the protocol and described in the ICF

Exclusion Criteria:

\- Have any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study (pregnancy is not exclusionary and pregnant women will be permitted to enroll in the study).

Where it's running

• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Study coordinator: Bilal A Siddiqui, MD
• Email: basiddiqui@mdanderson.org
• Phone: (713) 563-4600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IL-15–Enhanced NK Cell Therapy for Solid Tumors

  A first-in-human, early-phase study tests whether IL-15–enhanced engineered NK cells are safe and can show early signs of effect in adults with relapsed or metastatic solid tumors.

  Recruiting Early Phase 1 Genovn Therapeutics PTE. LTD. · Chongqing · NCT07621471

• LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases

  This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07594431

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• Support program for parents living with advanced cancer

  This study tests whether adding experiential sessions to a psycho-educational program helps parents with advanced cancer communicate better with their children aged 10–25.

  Recruiting Université Libre de Bruxelles · Anderlecht · NCT07341815

• POLARIS — Ablative radiotherapy with immunotherapy for people with multiple metastatic lesions

  This pilot tests whether giving focused high-dose radiation to up to 10 metastatic tumors while patients are on immunotherapy helps people with advanced solid tumors who have 3–10 metastases.

  Recruiting Phase 1 University of Illinois Chicago · Chicago, Illinois · NCT07269080

• Adding Y‑NM600 imaging and targeted Y‑90 radiation to anti‑PD‑1/PD‑L1 treatment for metastatic cancer

  This will test whether giving radioactive Y‑NM600 imaging and a targeted Y‑90 radiation dose to people with metastatic cancer who are on anti‑PD‑1 or anti‑PD‑L1 medicines is safe and can help those medicines work better.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT07197671

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.